Pillar 1 - FTO (new thread), page-12

It baffles me. The proof is in the heaps of pudding out there. It's just now a matter of showing it work in combinations clinically and in rac's own POC trials to realise the obvious gains to be made. I constantly find myself having to recheck what I've searched just to be sure. This pillar is the most exciting, with the greatest upside and risk - albeit significantly less risk than I've ever been invested in with regard to biotechs.

I've convinced myself that the drug is a diversified investment in its own right and have therefore let myself to be overweight in the stock. If one pillar falls (for a reason I've not really been able to foresee as a probable outcome so far) the other two stand unaffected. Each pillar covers 2-3+ disease processes themselves. We know the drug is safe, so that risk is out of the picture.

A lot of things can go wrong between now and buyout but I'd be surprised if it had anything to do with the drug itself.

The data is out there - now just up to RAC to prove it further (FTO ++) and package it nicely in a little acquisition bundle for the party/ies interested.

Happy New Year Everyone